UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'